Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

BioPharma Reporter

AUGUST 14, 2023

Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.

Reagent 98

Reagent Gene Therapy Life Science Manufacturing 98

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

BioPharma Reporter

FEBRUARY 22, 2024

MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a Â7 million Series A financing round, led by Mercia Ventures.

Gene 93

Gene Reagent Gene Therapy Production 93

Roots Analysis

APRIL 5, 2023

In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52

Reagent Marketing Gene Therapy Gene 52

Roots Analysis

JUNE 1, 2022

Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Kit Providers – Current Market Landscape. DNA Cloning Kits Market. DNA Cloning Reagent Providers – Current Market Landscape.

DNA 52

DNA Genetics Reagent Marketing 52

BioTech 365

SEPTEMBER 2, 2020

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)

Protein 40

Protein Gene Therapy Reagent Gene 40